NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas

Patients with neurofibromatosis type 1 (NF1) frequently develop plexiform neurofibromas (PNs), which can cause significant morbidity. We performed a phase II trial of the MAPK/ERK kinase inhibitor, mirdametinib (PD-0325901), in patients with NF1 and inoperable PNs. The primary objective was response...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Weiss, Brian D., Wolters, Pamela L., Plotkin, Scott R., Widemann, Brigitte C., Tonsgard, James H., Blakeley, Jaishri, Allen, Jeffrey C., Schorry, Elizabeth, Korf, Bruce, Robison, Nathan J., Goldman, Stewart, Vinks, Alexander A., Emoto, Chie, Fukuda, Tsuyoshi, Robinson, Coretta T., Cutter, Gary, Edwards, Lloyd, Dombi, Eva, Ratner, Nancy, Packer, Roger, Fisher, Michael J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2021
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078274/
https://ncbi.nlm.nih.gov/pubmed/33507822
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02220
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados